Form 4: Edesa Biotech CEO Pardeep Nijhawan Reports Acquisition of 2,765 Common Shares

Edesa Biotech's CEO, Pardeep Nijhawan, reports acquiring 2,765 common shares through a grant of restricted share units, bringing his total direct holdings to 107,810 shares.

Summary

• On March 1, 2024, Pardeep Nijhawan, CEO of Edesa Biotech, Inc., acquired 2,765 common shares.
• The acquisition was a result of a grant of restricted share units under the company's 2019 Equity Incentive Compensation Plan, which vested fully upon grant.
• The price per share for this transaction was $0.
• Following the transaction, Nijhawan directly owns 107,810 common shares.
• Nijhawan also has indirect ownership through several entities: Pardeep Nijhawan Medicine Professional Corporation (336,702 shares), The New Nijhawan Family Trust 2015 (32,609 shares), The Digestive Health Clinic Inc (32,013 shares), and 1968160 Ontario Inc (53,104 shares).
• Nijhawan disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing a transaction. The acquisition of shares by the CEO could be seen as a positive signal, but it's part of a pre-existing compensation plan.

Positives

• The acquisition of shares by the CEO could be interpreted positively, signaling confidence in the company's future prospects.
• The grant of restricted share units aligns the CEO's interests with those of the shareholders.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, and it provides transparency into the trading activities of key personnel at Edesa Biotech.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates the CEO's confidence in the company.

Key Dates

Keywords

Edesa Biotech, Pardeep Nijhawan, common shares, restricted share units, beneficial ownership, EDSA, insider trading